Literature DB >> 35802163

Isolation, typing, and drug susceptibility of Leishmania (Leishmania) infantum isolates from dogs of the municipality of Embu das Artes, an endemic region for canine leishmaniasis in Brazil.

Bianca A Ferreira1, Thaynan F C Martins2, Elizabeth M Coser1, Viviane da L Oliveira1, Edite H Yamashiro-Kanashiro2,3, Mussya C Rocha3, Marcelo M Pinto4, Paulo C Cotrim2, Adriano C Coelho5.   

Abstract

The parasitic protozoa Leishmania (Leishmania) infantum is the etiological agent of human visceral leishmaniasis and canine leishmaniasis in South America, where Brazil is the most affected country. This zoonotic disease is transmitted by the bite of an infected phlebotomine sand fly and dogs constitute the main domestic reservoir of the parasite. In this study, we screened 2348 dogs of the municipality of Embu das Artes, Brazil, for antibodies against the parasite. Prevalence for canine leishmaniasis seropositivity was 2.81%, as assessed using a Dual-Path Platform rapid test for canine leishmaniasis. Twenty-five seropositive dogs were euthanized for parasite isolation and 14 isolates were successful obtained. Nucleotide sequencing of the internal transcribed spacer confirmed the isolates to be L. (L.) infantum, and very low sequence variability was observed among them. The in vitro susceptibility to miltefosine and paromomycin was assessed and moderate variation in paromomycin susceptibility was found among the isolates in the promastigote and intracellular amastigote stages. On the other hand, in vitro susceptibility to miltefosine of these isolates was homogenous, particularly in the amastigote stage (EC50 values from 0.69 to 2.07 μM). In addition, the miltefosine sensitivity locus was deleted in all the isolates, which does not corroborate the hypothesis that the absence of this locus is correlated with a low in vitro susceptibility. Our findings confirm that the municipality of Embu das Artes is endemic for canine leishmaniasis and that isolates from this region are susceptible to paromomycin and miltefosine, indicating the potential of these drugs to be clinically evaluated in the treatment of human visceral leishmaniasis in Brazil.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Canine leishmaniasis; Drug susceptibility; Leishmania (Leishmania) infantum; Miltefosine; Paromomycin

Mesh:

Substances:

Year:  2022        PMID: 35802163     DOI: 10.1007/s00436-022-07594-5

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.383


  71 in total

1.  Canine visceral leishmaniasis: perception, prevalence, and spatial distribution in municipality of Nossa Senhora do Livramento, Mato Grosso, Brazil.

Authors:  Matheus Roberto Carvalho; Álvaro Felipe de Lima Ruy Dias; Arleana do Bom Parto Ferreira de Almeida; Mário Ribeiro Alves; Adilson Santos Paes; Valéria Régia Franco Sousa
Journal:  Rev Bras Parasitol Vet       Date:  2020-05-18

2.  Treatment of canine leishmaniosis with aminosidine at an optimized dosage regimen: a pilot open clinical trial.

Authors:  L V Athanasiou; M N Saridomichelakis; V I Kontos; G Spanakos; T S Rallis
Journal:  Vet Parasitol       Date:  2012-10-23       Impact factor: 2.738

Review 3.  Canine leishmaniasis.

Authors:  Jorge Alvar; Carmen Cañavate; Ricardo Molina; Javier Moreno; Javier Nieto
Journal:  Adv Parasitol       Date:  2004       Impact factor: 3.870

Review 4.  Leishmaniasis.

Authors:  Sakib Burza; Simon L Croft; Marleen Boelaert
Journal:  Lancet       Date:  2018-08-17       Impact factor: 79.321

Review 5.  Canine leishmaniosis - new concepts and insights on an expanding zoonosis: part one.

Authors:  Gad Baneth; Alexander F Koutinas; Laia Solano-Gallego; Patrick Bourdeau; Lluis Ferrer
Journal:  Trends Parasitol       Date:  2008-05-29

6.  Introduction and expansion of human American visceral leishmaniasis in the state of Sao Paulo, Brazil, 1999-2011.

Authors:  Marisa Furtado Mozini Cardim; Lilian A Colebrusco Rodas; Margareth Regina Dibo; Marluci Monteiro Guirado; Agda Maria Oliveira; Francisco Chiaravalloti-Neto
Journal:  Rev Saude Publica       Date:  2013-08       Impact factor: 2.106

7.  Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India.

Authors:  Sujit K Bhattacharya; T K Jha; Shyam Sundar; C P Thakur; Juergen Engel; Herbert Sindermann; Klaus Junge; Juntra Karbwang; Anthony D M Bryceson; Jonathan D Berman
Journal:  Clin Infect Dis       Date:  2003-12-18       Impact factor: 9.079

8.  A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis.

Authors:  Juliana B T Carnielli; Kathryn Crouch; Sarah Forrester; Vladimir Costa Silva; Sílvio F G Carvalho; Jeziel D Damasceno; Elaine Brown; Nicholas J Dickens; Dorcas L Costa; Carlos H N Costa; Reynaldo Dietze; Daniel C Jeffares; Jeremy C Mottram
Journal:  EBioMedicine       Date:  2018-09-27       Impact factor: 8.143

9.  Natural Resistance of Leishmania infantum to Miltefosine Contributes to the Low Efficacy in the Treatment of Visceral Leishmaniasis in Brazil.

Authors:  Juliana B T Carnielli; Renata Monti-Rocha; Dorcas Lamounier Costa; Aretha Molina Sesana; Laura N N Pansini; Marcela Segatto; Jeremy C Mottram; Carlos Henrique Nery Costa; Sílvio F G Carvalho; Reynaldo Dietze
Journal:  Am J Trop Med Hyg       Date:  2019-10       Impact factor: 2.345

10.  Coupling chemical mutagenesis to next generation sequencing for the identification of drug resistance mutations in Leishmania.

Authors:  Arijit Bhattacharya; Philippe Leprohon; Sophia Bigot; Prasad Kottayil Padmanabhan; Angana Mukherjee; Gaétan Roy; Hélène Gingras; Anais Mestdagh; Barbara Papadopoulou; Marc Ouellette
Journal:  Nat Commun       Date:  2019-12-09       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.